Immuno-PET for Clinical Theranostic Approaches
AbstractRecent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals. View Full-Text
Share & Cite This Article
Bailly, C.; Cléry, P.-F.; Faivre-Chauvet, A.; Bourgeois, M.; Guérard, F.; Haddad, F.; Barbet, J.; Chérel, M.; Kraeber-Bodéré, F.; Carlier, T.; Bodet-Milin, C. Immuno-PET for Clinical Theranostic Approaches. Int. J. Mol. Sci. 2017, 18, 57.
Bailly C, Cléry P-F, Faivre-Chauvet A, Bourgeois M, Guérard F, Haddad F, Barbet J, Chérel M, Kraeber-Bodéré F, Carlier T, Bodet-Milin C. Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences. 2017; 18(1):57.Chicago/Turabian Style
Bailly, Clément; Cléry, Pierre-François; Faivre-Chauvet, Alain; Bourgeois, Mickael; Guérard, François; Haddad, Ferid; Barbet, Jacques; Chérel, Michel; Kraeber-Bodéré, Françoise; Carlier, Thomas; Bodet-Milin, Caroline. 2017. "Immuno-PET for Clinical Theranostic Approaches." Int. J. Mol. Sci. 18, no. 1: 57.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.